E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter

About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Become a Fan

« Eli Lilly & Co. v. Actavis Elizabeth LLC (Fed. Cir. 2011) | Main | Forum on European Pharmaceutical Regulatory Law »

August 11, 2011



Frankly, Waxman and his liberal cohorts need to "get a life" and some semblance of "reality" when it comes to biosimilars. Just like the rest of the world needs to realize there's no "free lunch" (aka by imposing price controls on drugs) when it comes to drug development.

The comments to this entry are closed.

October 2015

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31